[HTML][HTML] Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a …
…, N Brooks, M Smaja, G Mircus, K Pan, J Southern… - The Lancet, 2021 - thelancet.com
Background Following the emergency use authorisation of the Pfizer–BioNTech mRNA
COVID-19 vaccine BNT162b2 (international non-proprietary name tozinameran) in Israel, the …
COVID-19 vaccine BNT162b2 (international non-proprietary name tozinameran) in Israel, the …
[HTML][HTML] Severity of Omicron (B. 1.1. 529) and Delta (B. 1.617. 2) SARS-CoV-2 infection among hospitalised adults: A prospective cohort study in Bristol, United …
Background There is an urgent public health need to evaluate disease severity in adults
hospitalised with Delta and Omicron SARS-CoV-2 variant infections. However, limited data exist …
hospitalised with Delta and Omicron SARS-CoV-2 variant infections. However, limited data exist …
Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer–BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a …
…, N Brooks, M Smaja, K Pan, J Southern… - The Lancet Infectious …, 2022 - thelancet.com
Background On Dec 20, 2020, Israel initiated a nationwide COVID-19 vaccination campaign
for people aged 16 years and older and exclusively used the Pfizer–BioNTech BNT162b2 …
for people aged 16 years and older and exclusively used the Pfizer–BioNTech BNT162b2 …
[HTML][HTML] Prognostic value of interferon-γ release assays and tuberculin skin test in predicting the development of active tuberculosis (UK PREDICT TB): a prospective …
I Abubakar, F Drobniewski, J Southern… - The Lancet Infectious …, 2018 - thelancet.com
Background Tackling tuberculosis requires testing and treatment of latent tuberculosis in
high-risk groups. The aim of this study was to estimate the predictive values of the tuberculin …
high-risk groups. The aim of this study was to estimate the predictive values of the tuberculin …
Antibody responses after primary immunization in infants born to women receiving a pertussis-containing vaccine during pregnancy: single arm observational study …
SN Ladhani, NJ Andrews, J Southern… - Clinical infectious …, 2015 - academic.oup.com
Introduction. In England, antenatal pertussis immunization using a tetanus/low-dose
diphtheria/5-component acellular-pertussis/inactivated-polio (TdaP 5 /IPV) vaccine was introduced …
diphtheria/5-component acellular-pertussis/inactivated-polio (TdaP 5 /IPV) vaccine was introduced …
The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50–80 years
D Goldblatt, J Southern, N Andrews… - Clinical Infectious …, 2009 - academic.oup.com
Background. Infections with pneumococci are a major cause of morbidity and mortality in
the elderly population. Although 23-valent pneumococcal polysaccharide vaccine (PPV) is …
the elderly population. Although 23-valent pneumococcal polysaccharide vaccine (PPV) is …
[HTML][HTML] Pneumococcal conjugate vaccine 13 delivered as one primary and one booster dose (1+ 1) compared with two primary doses and a booster (2+ 1) in UK …
D Goldblatt, J Southern, NJ Andrews… - The Lancet Infectious …, 2018 - thelancet.com
Background Infants in the UK were first offered a pneumococcal conjugate vaccine (PCV7)
in 2006, given at 2 and 4 months of age and a booster dose at 13 months (2 + 1 schedule). A …
in 2006, given at 2 and 4 months of age and a booster dose at 13 months (2 + 1 schedule). A …
[HTML][HTML] Pneumococcal carriage in children and their household contacts six years after introduction of the 13-valent pneumococcal conjugate vaccine in England
J Southern, N Andrews, P Sandu, CL Sheppard… - PLoS …, 2018 - journals.plos.org
Background In April 2010, 13-valent pneumococcal conjugate vaccine (PCV13) replaced
PCV7 in the infant immunisation schedule in England and Wales. Despite limited serotype …
PCV7 in the infant immunisation schedule in England and Wales. Despite limited serotype …
Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers
D Goldblatt, J Southern, L Ashton… - The Pediatric …, 2006 - journals.lww.com
Background: The minimum number of doses of pneumococcal conjugate vaccine required
for protection is not known. We studied the immunogenicity of a reduced schedule in infants …
for protection is not known. We studied the immunogenicity of a reduced schedule in infants …
[HTML][HTML] Safety of live attenuated influenza vaccine in atopic children with egg allergy
Background Live attenuated influenza vaccine (LAIV) is an intranasal vaccine recently
incorporated into the United Kingdom immunization schedule. However, it contains egg protein …
incorporated into the United Kingdom immunization schedule. However, it contains egg protein …